Hit a Record High

FDA Approves New Teva Schizophrenia Treatment — Stock Jumps

Teva stock
Teva stock | Photo: Shutterstock

Teva announced that the U.S. Food and Drug Administration (FDA) approved WELTRUZA, a long-acting treatment for schizophrenia in adults. The new treatment is administered as a once-monthly subcutaneous injection. According to the company, it is the first and only treatment based on the active ingredient olanzapine to be administered monthly via subcutaneous injection.

The drug is expected to be available in the United States in the coming weeks, and it will be marketed in three different doses of 318, 425 and 531 milligrams, equivalent to daily doses of 10, 15 and 20 milligrams of oral olanzapine, respectively.

Teva | Photo: Shutterstock

The new drug is based on olanzapine, an active ingredient used for more than 30 years to treat schizophrenia. The treatment is intended to address one of the most significant challenges in treating the disease: patients’ difficulty adhering to daily medication. According to Teva, the new treatment does not require loading doses, does not require supplemental oral medication and does not require medical monitoring after the injection.

What Did the Clinical Trial Results Show?

The approval was based on the results of an advanced Phase 3 clinical trial called SOLARIS. According to the company, the trial showed an improvement in disease symptoms, a reduction in severity and an improvement in patients’ personal and social functioning. The systemic safety profile observed was consistent with the known profile of oral olanzapine. However, the treatment involves risks and side effects.

The clinical trial reported, among other things, weight gain, drowsiness, headaches, constipation and injection-site reactions. Metabolic changes were also observed, consistent with the known safety profile of olanzapine, including the possibility of significant weight gain.

Richard Francis, Teva president and CEO. Photo: Elad Malka
Richard Francis, Teva president and CEO | Photo: Elad Malka

Teva’s Strategy and Expansion into Europe

Dr. Eric Hughes, executive vice president, head of global research and development and chief medical officer at Teva, said the approval reflects the company’s innovation and research capabilities. He said combining existing scientific knowledge with the development of a new formulation makes it possible to address a significant barrier in schizophrenia treatment and improve treatment options for people living with the disease.

The approval in the United States adds to Teva’s efforts to expand its activity in the central nervous system field and develop treatments with a distinct clinical advantage as part of the company’s growth strategy.

Alongside the approval in the United States, Teva continues to advance the approval process for a long-acting olanzapine-based treatment in Europe as well. The European Medicines Agency (EMA) accepted the marketing authorization application for the treatment in May 2026, but it has not yet been approved in Europe.

Key takeaways

  • Teva said the FDA approved WELTRUZA, a long-acting schizophrenia treatment for adults.
  • The treatment is a once-monthly subcutaneous injection and, according to Teva, is the first and only olanzapine-based treatment given monthly this way.
  • Teva said the drug is expected to be available in the United States in the coming weeks and will be sold in three doses: 318, 425 and 531 milligrams.
  • The approval was based on the Phase 3 SOLARIS trial, which showed improvement in symptoms, severity and personal and social functioning.
  • Teva is also continuing to pursue approval of a long-acting olanzapine-based treatment in Europe, where it has not yet been approved.

Questions and answers

What did the FDA approve for Teva?
The FDA approved WELTRUZA, Teva’s long-acting treatment for schizophrenia in adults. Teva said it is administered as a once-monthly subcutaneous injection.
What did Teva say about the clinical trial results?
Teva said the Phase 3 SOLARIS trial showed improvement in disease symptoms, reduced severity, and better personal and social functioning. The company also said the safety profile was consistent with oral olanzapine, though the treatment has risks and side effects.
Is Teva seeking approval in Europe too?
Yes. Teva said it is advancing the approval process for a long-acting olanzapine-based treatment in Europe. The European Medicines Agency accepted the marketing authorization application in May 2026, but it has not yet been approved there.

Share this story

About the writer

TV10 Editorial Staff

Writes for TV10, Israel’s economic channel. This story was translated from the original Hebrew.

More stories by TV10 Editorial Staff

More for you